- Viking Therapeutics posts a first-quarter loss, narrowly missing analyst expectations.
- Company cash holdings show a decline year-over-year, impacting financial strategy.
- Analysts foresee significant upside potential with a strong "Outperform" consensus.
Viking Therapeutics (NASDAQ: VKTX) recently released its financial results for the first quarter, reporting a GAAP loss per share of $0.41. This figure came in $0.06 below what analysts had anticipated. As of March 31, 2025, Viking Therapeutics' cash position, which includes cash equivalents and short-term investments, stood at $852 million—a decrease from $903 million at the conclusion of 2024.
Wall Street Analysts' Expectations
According to the latest forecasts provided by 15 analysts, the average one-year price target for Viking Therapeutics Inc (VKTX, Financial) is $93.13. Estimates vary widely, with the highest target priced at $125.00 and the lowest at $30.00. The average price target indicates a notable upside of 261.26% from the current trading price of $25.78. Investors interested in more detailed forecast data can explore further on the Viking Therapeutics Inc (VKTX) Forecast page.
Brokerage Recommendations
Viking Therapeutics Inc (VKTX, Financial) enjoys a robust average brokerage recommendation of 1.7, marking the stock as an "Outperform." This recommendation is derived from assessments by 18 brokerage firms. On the rating scale, a score of 1 represents a Strong Buy, while a 5 indicates a Sell.
With the recent financial performance and prevailing analyst sentiment, Viking Therapeutics remains an intriguing prospect for investors eyeing potential growth in the biotech sector.
